Skip to content

Trial Summary

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Acronym:

DUO-E

ACTRN/NCT /ethics:

NCT04269200

Scientific title:

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Sponsor / Cooperative group:

AstraZeneca

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-05-21
Anticipated End Date2023-09-26

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Shawgi Sukumaran
Recruitment StatusRecruitment on hold